Results 161 to 170 of about 4,200 (201)
Neurohumoral Effects of Aliskiren in Patients With Symptomatic Heart Failure Receiving a Mineralocorticoid Receptor Antagonist: The Aliskiren Observation of Heart Failure Treatment Study [PDF]
European Journal of Heart Failure, 2011 Aims We evaluated the influence of concomitant mineralocorticoid receptor antagonists (MRAs) on the safety and neurohumoral effects of a direct renin inhibitor in the ALiskiren Observation of Heart Failure Treatment (ALOFT) study.
Bertram Pitt +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
RENIN INHIBITION WITH ALISKIREN
Clinical and Experimental Pharmacology and Physiology, 2008SUMMARY Initial attempts to inhibit renin in humans have faced numerous difficulties. Molecular modelling and X‐ray crystallography of the active site of renin have led to the development of new orally active renin inhibitors, such as aliskiren. Aliskiren has a low bioavailality (between 2.6 and 5.0%) compensated by its high potency to inhibit renin ...
Grégoire, Wuerzner, Michel, Azizi
openaire +2 more sources
Aliskiren in the Management of Hypertension
American Journal Cardiovascular Drugs, 2010Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers) have been shown to be effective drugs in the management of hypertension and to have beneficial effects along the cardiovascular continuum.
Vivencio, Barrios, Carlos, Escobar
openaire +2 more sources
Is There a Place on the Shelf for Aliskiren?
Current Cardiovascular Risk Reports, 2010Increased renin-angiotensin-aldosterone system (RAAS) activity contributes to target-organ damage and increases cardiovascular risk by elevating blood pressure (BP) and through direct effects on the heart, kidneys, brain, and vascular endothelium. Pharmacologic blockade of RAAS effectively reduces BP and limits or reverses various forms of target-organ
openaire +3 more sources
▼Aliskiren for hypertension in adults
Drug and Therapeutics Bulletin, 2008High blood pressure is a major risk factor for cardiovascular disease worldwide.1 Drug treatments include those that target the renin-angiotensin system, a key hormone cascade in the regulation of blood pressure. One of these is ▼aliskiren (Rasilez – Novartis), which belongs to a new class of drugs, direct renin inhibitors.2 Here we assess its place in
openaire +2 more sources